KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Capital Expenditures (2016 - 2025)

Historic Capital Expenditures for AbbVie (ABBV) over the last 14 years, with Q3 2025 value amounting to $381.0 million.

  • AbbVie's Capital Expenditures rose 5301.2% to $381.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.2 billion, marking a year-over-year increase of 3243.24%. This contributed to the annual value of $974.0 million for FY2024, which is 2535.39% up from last year.
  • Per AbbVie's latest filing, its Capital Expenditures stood at $381.0 million for Q3 2025, which was up 5301.2% from $269.0 million recorded in Q2 2025.
  • In the past 5 years, AbbVie's Capital Expenditures ranged from a high of $381.0 million in Q3 2025 and a low of $143.0 million during Q2 2022
  • Moreover, its 5-year median value for Capital Expenditures was $205.0 million (2023), whereas its average is $216.7 million.
  • Its Capital Expenditures has fluctuated over the past 5 years, first crashed by 3297.49% in 2021, then soared by 5301.2% in 2025.
  • Over the past 5 years, AbbVie's Capital Expenditures (Quarter) stood at $187.0 million in 2021, then rose by 13.9% to $213.0 million in 2022, then fell by 3.76% to $205.0 million in 2023, then surged by 41.95% to $291.0 million in 2024, then soared by 30.93% to $381.0 million in 2025.
  • Its Capital Expenditures stands at $381.0 million for Q3 2025, versus $269.0 million for Q2 2025 and $235.0 million for Q1 2025.